Literature DB >> 27324025

Structural allograft reconstruction of the foot and ankle after tumor resections.

M A Ayerza1, N S Piuzzi2, L A Aponte-Tinao2, G L Farfalli2, D L Muscolo2.   

Abstract

BACKGROUND: Structural allografts have been used to correct deformities or to fill bone defects secondary to tumor excisions, trauma, osteochondral lesions, or intercalary arthrodesis. However, the quality of published evidence supporting the use of allograft transplantation in foot and ankle surgery has been reported as fair. The purpose of this study was to report the overall survival of structural allograft in the foot and ankle after tumor resection, and the survival according to the type of allograft and the complication rates in the medium to long term.
MATERIALS AND METHODS: From January 1989 to June 2011, 44 structural allograft reconstructions of the foot and ankle were performed in 42 patients (28 men and 14 women) due to musculoskeletal tumor resections. Mean age at presentation was 27 years. Mean follow-up was 53 months. Demographic data, diagnosis, site of the neoplasm, operations performed, operative complications, outcomes after surgery, date of last follow-up evaluation, and local recurrences were reviewed for all patients. Regarding the type of 44 allograft reconstructions, 16 were hemicylindrical allografts (HA), 12 intercalary allografts (IA), 10 osteoarticular allografts (OA), and 6 were total calcaneal allograft (CA).
RESULTS: The overall allograft survival rate, as calculated with the Kaplan-Meier method, at 5 and 10 years was 79 % (95 % CI 64-93 %). When allocated by type of allograft reconstruction the specific allograft survival at 5 and 10 years was: 83 % for CA, 80 % for HA, 77 % for OA, and 75 % for IA. The complications rate for this series was 36 % including: articular failure, local recurrence, infection, fracture and nonunion.
CONCLUSION: This study showed that structural allograft reconstruction in the foot and ankle after tumor resection may be durable with a 79 % survival rate at 5 and 10 years. The two types of allografts that showed better survival rate were hemicylindrical allografts (80 %) and calcaneus allografts (83 %). The highest complication rates occurred after calcaneus allografts and osteoarticular allografts. LEVEL OF EVIDENCE: IV.

Entities:  

Keywords:  Bone transplantation; Fresh-frozen structural allografts; Limb salvage; Tumor of bone; Tumors foot and ankle

Mesh:

Year:  2016        PMID: 27324025     DOI: 10.1007/s12306-016-0413-4

Source DB:  PubMed          Journal:  Musculoskelet Surg        ISSN: 2035-5114


  43 in total

1.  Osteosarcoma of the calcaneus treated with prosthetic replacement with twelve years of followup: a case report.

Authors:  Loretta B Chou; Martin M Malawer
Journal:  Foot Ankle Int       Date:  2007-07       Impact factor: 2.827

2.  Total calcanectomy and reconstruction with vascularized iliac bone graft for osteoblastoma: a report of two cases.

Authors:  Guido Scoccianti; Domenico Andrea Campanacci; Marco Innocenti; Giovanni Beltrami; Rodolfo Capanna
Journal:  Foot Ankle Int       Date:  2009-07       Impact factor: 2.827

Review 3.  The application of allograft bone in foot and ankle surgery.

Authors:  A Catanzariti; L Karlock
Journal:  J Foot Ankle Surg       Date:  1996 Sep-Oct       Impact factor: 1.286

Review 4.  Autologous bone graft harvesting: a review of grafts and surgical techniques.

Authors:  A M Jakoi; J A Iorio; P J Cahill
Journal:  Musculoskelet Surg       Date:  2015-04-07

5.  Allografts in Foot and Ankle Surgery: A Critical Analysis Review.

Authors:  John S Lewis; Samuel B Adams; James A Nunley; Mark E Easley
Journal:  JBJS Rev       Date:  2013-11-26

6.  Treatment of primary malignant bone tumours of the distal tibia.

Authors:  M Laitinen; J Hardes; H Ahrens; C Gebert; B Leidinger; M Langer; W Winkelmann; G Gosheger
Journal:  Int Orthop       Date:  2005-06-11       Impact factor: 3.075

7.  Surgical treatment of malignant tumors of the foot and ankle.

Authors:  Harzem Ozger; Levent Eralp; Mehmet Türker; Mert Basaran
Journal:  Int J Clin Oncol       Date:  2005-04       Impact factor: 3.402

Review 8.  Use of structural allograft to compensate for bone loss in arthrodesis of the foot and ankle.

Authors:  Steven K Neufeld; Jaime Uribe; Mark S Myerson
Journal:  Foot Ankle Clin       Date:  2002-03       Impact factor: 1.653

9.  Fresh osteochondral total ankle allograft transplantation for the treatment of ankle arthritis.

Authors:  Clifford L Jeng; Anish Kadakia; Kacey L White; Mark S Myerson
Journal:  Foot Ankle Int       Date:  2008-06       Impact factor: 2.827

10.  Hemicortical allograft reconstruction after resection of low-grade malignant bone tumours.

Authors:  R L M Deijkers; R M Bloem; P C W Hogendoorn; J J Verlaan; H M Kroon; A H M Taminiau
Journal:  J Bone Joint Surg Br       Date:  2002-09
View more
  5 in total

1.  Higher local recurrence rates after intralesional surgery for giant cell tumor of the proximal femur compared to other sites.

Authors:  Costantino Errani; Shinji Tsukamoto; Giulio Leone; Manabu Akahane; Luca Cevolani; Piergiuseppe Tanzi; Akira Kido; Kanya Honoki; Yasuhito Tanaka; Davide Maria Donati
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-06-06

Review 2.  Present day controversies and consensus in curettage for giant cell tumor of bone.

Authors:  Costantino Errani; Shinji Tsukamoto; Giovanni Ciani; Davide Maria Donati
Journal:  J Clin Orthop Trauma       Date:  2019-10-11

3.  Malignant tumours of the foot and ankle.

Authors:  E Mascard; N Gaspar; L Brugières; C Glorion; S Pannier; A Gomez-Brouchet
Journal:  EFORT Open Rev       Date:  2017-05-11

4.  Medial Femoral Condyle Free Flap Reconstruction of Complex Foot and Ankle Pathology.

Authors:  John T Stranix; Merisa L Piper; Said C Azoury; Geoffrey Kozak; Oded Ben-Amotz; Keith L Wapner; L Scott Levin
Journal:  Foot Ankle Orthop       Date:  2019-11-07

5.  Midterm outcomes of midfoot and hindfoot arthrodesis with strut allograft for Müller-Weiss disease.

Authors:  Tung-Ying Lee; Chang-Chin Wu; Kai-Chiang Yang; Kuang-Ting Yeh; Ing-Ho Chen; Chen-Chie Wang
Journal:  BMC Musculoskelet Disord       Date:  2022-07-27       Impact factor: 2.562

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.